KEATING LAURIE

SEC source: 0001193125-26-330530 · ownership.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2036-07-31

F1 · derivative.exercise_date: The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.

SEC source: 0001835597-26-000028 · form4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,000

Underlying: Common Stock · 34,000 shares

Expires 2036-06-17

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001790340-26-000066 · wk-form4_1781213173.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-26-000004 · wk-form4_1767390971.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,888

Underlying: Class A Common Stock · 7,888 shares

Expires 2036-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

SEC source: 0001790340-25-000071 · wk-form4_1750079353.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

SEC source: 0001127602-25-016930 · form4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001790340-25-000005 · wk-form4_1735851984.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,485

Underlying: Class A Common Stock · 23,485 shares

Expires 2035-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

SEC source: 0001127602-24-019123 · form4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 13,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001628280-24-028065 · wk-form4_1718310166.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-24-000004 · wk-form4_1704231077.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,879

Underlying: Class A Common Stock · 6,879 shares

Expires 2034-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

SEC source: 0001127602-23-019407 · form4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2033-06-21

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

SEC source: 0001790340-23-000039 · wk-form4_1686861839.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Class A Common Stock · 17,500 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first.

SEC source: 0000899243-23-001609 · doc4.xml · derivative · entry 2

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires 2032-05-31

F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.

F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.

SEC source: 0000899243-23-001609 · doc4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,809 shares

Expires 2031-11-16

F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.

F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.

SEC source: 0001415889-22-006897 · form4-06232022_010649.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,200

Underlying: Class A Common Stock · 14,200 shares

Expires 2032-06-20

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first.

SEC source: 0001567619-22-012295 · doc1.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,904

Underlying: Common Stock · 11,904 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2023 of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

SEC source: 0001415889-22-005150 · form4-05172022_020524.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

SEC source: 0000899243-22-017498 · doc4.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 5,833 shares

Expires 2032-05-05

F1 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date.

SEC source: 0001127602-23-001831 · form4.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,166

SEC source: 0001567619-21-020884 · doc1.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,809

Underlying: Common Stock · 23,809 shares

Expires 2031-11-16

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares initially subject to the option will vest on each monthly anniversary measured from November 17, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001735276-21-000079 · edgardoc.xml · derivative · entry 6

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,124

Underlying: Common Stock · 7,876 shares

Expires 2025-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000079 · edgardoc.xml · derivative · entry 5

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,876

Underlying: Common Stock · 2,124 shares

Expires 2025-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000079 · edgardoc.xml · nonDerivative · entry 3

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,132

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000079 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,132

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000079 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001104659-21-099736 · tm2123807-7_4seq1.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

SEC source: 0001735276-21-000053 · edgardoc.xml · derivative · entry 7

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 5,000 shares

Expires 2025-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000053 · edgardoc.xml · derivative · entry 6

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,188

Underlying: Common Stock · 1,812 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000053 · edgardoc.xml · nonDerivative · entry 4

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,132

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000053 · edgardoc.xml · nonDerivative · entry 3

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,132

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000053 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,944

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000053 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,944

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000047 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,132

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000038 · edgardoc.xml · nonDerivative · entry 3

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,866

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-21-000038 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,941

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-21-000038 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,955

F1 · kind: On February 26, 2020, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2019 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and one-third of the PSU award vested as of April 19, 2021.

SEC source: 0001735276-21-000022 · edgardoc.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,846

Underlying: Common Stock · 17,846 shares

Expires 2031-02-23

F1 · shares: Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2020. The reporting person also received 9,566 performance stock units that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest.

F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000011 · edgardoc.xml · nonDerivative · entry 3

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,437

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-21-000011 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,543

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-21-000011 · edgardoc.xml · derivative · entry 5

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 4,584 shares

Expires 2028-03-01

F4 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock in connection with the 2017 year-end compensation review. One third of the shares subject to the option vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the third performance criterion was met and the option vested as to the final one third of the shares as of February 11, 2021.

SEC source: 0001735276-21-000011 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,400

F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and an additional one-third of the PSU award vested as of February 11, 2021.

SEC source: 0001735276-21-000006 · edgardoc.xml · derivative · entry 8

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 6,000 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000006 · edgardoc.xml · derivative · entry 7

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,164

Underlying: Common Stock · 3,027 shares

Expires 2024-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000006 · edgardoc.xml · nonDerivative · entry 5

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,234

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000006 · edgardoc.xml · nonDerivative · entry 4

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,261

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000006 · edgardoc.xml · nonDerivative · entry 3

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,261

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000006 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000006 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

SEC source: 0001735276-21-000004 · edgardoc.xml · derivative · entry 8

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,191

Underlying: Common Stock · 13,000 shares

Expires 2024-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-21-000004 · edgardoc.xml · derivative · entry 7

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,370

Underlying: Common Stock · 1,941 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 10, 2020.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.